Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: A randomized clinical trial

AIDS Research and Human Retroviruses

Volumn 30, Issue 5, 2014, Pages 425-433

  Torres, Berta ^a   Rallón, Norma I ^b   Loncá, Montserrat ^a   Díaz, Alba ^a   Alós, Llucia ^a   Martínez, Esteban ^a   Cruceta, Anna ^a   Arnaiz, Joan Albert ^a   Leal, Lorna ^a   Lucero, Constanza ^a   León, Agathe ^a   Sánchez, Marcelo ^a   Negredo, Eugenia ^c   Clotet, Bonaventura ^c   Gatell, José M ^a   Benito, José M ^b   Garcia, Felipe ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; EMTRICITABINE; INTERLEUKIN 7 RECEPTOR; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; LOPINAVIR; RITONAVIR;

ADULT; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EXHAUSTION; FEMALE; FIBROSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LYMPHOID TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SENESCENCE; TREATMENT DURATION; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNE SYSTEM; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; LOPINAVIR; MALE; MIDDLE AGED; RITONAVIR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899833683     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0185     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860
2. Thompson MA, Aberg JA, Hoy JF, et al.: Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308(4):387-402
3. Riddler SA, Haubrich R, DiRienzo AG, et al.: Classsparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-2106
4. Manfredi R, Calza L, and Chiodo F: First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS 2004;18(17):2331-2333
5. Torti C, Maggiolo F, Patroni A, et al.: Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenzbased HAART regimens in antiretroviral-naive HIVpositive patients: Results from the Italian MASTER Cohort. J Antimicrobe Chemother 2005;56(1):190-195
6. Barreiro P, Soriano V, Casas E, and Gonzalez-Lahoz J: Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002;16(2):245-249
7. Echeverria P, Negredo E, Carosi G, et al.: Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naive patients: A 48-week, multicentre, randomized study (Lake Study). Antiviral Res 2010;85(2): 403-408
8. MacArthur RD, Novak RM, Peng G, et al.: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): A long-term randomised trial. Lancet 2006;368(9553):2125-2135
9. De Luca A, Cozzi-Lepri A, Antinori A, et al.: Lopinavir/ ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: A non-randomized comparison. Antiviral Ther 2006;11(5):609-618
10. Portsmouth S, Stebbing J, Gill J, et al.: A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003;17(11):F17-22
11. Rates of disease progression according to initial highly active antiretroviral therapy regimen: A collaborative analysis of 12 prospective cohort studies. J Infect Dis 2006;194(5):612-622
12. Moore DM, Harris R, Lima V, et al.: Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr 2009;52(3):357-363
13. Marchetti G, Merlini E, Sinigaglia E, et al.: Immune reconstitution in HIV + subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4 + . Curr HIV Res 2012;10(7):597-605
14. Plana M, Garcia F, Gallart T, et al.: Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000;14(13):1921-1933
15. Plana M, Ferrer E, Martinez C, et al.: Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/ lamivudine plus nelfinavir or nevirapine. Antiviral Ther 2004;9(2):197-204
16. Rizzardini G, Trabattoni D, Capetti A, et al.: An immunological comparison of third companion in advanced drug-naive HIV-infected patients. HIV Clin Trials 2006;7(5):221-228
17. Gandhi RT, Spritzler J, Chan E, et al.: Effect of baselineand treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384. J Acquir Immune Defic Syndr 2006;42(4):426-434
18. Funderburg N, Kalinowska M, Eason J, et al.: Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4 + cell rises in HIV-infected patients. PloS One 2010;5(10):e13188
19. Franco JM, Rubio A, Martinez-Moya M, et al.: T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002;99(10):3702-3706
20. McCune JM, Loftus R, Schmidt DK, et al.: High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998;101(11):2301-2308
21. Esser MT, Marchese RD, Kierstead LS, et al.: Memory T cells and vaccines. Vaccine 2003;21(5-6):419-430
22. Hua W, Jiao Y, Zhang H, et al.: Central memory CD4 cells are an early indicator of immune reconstitution in HIV/ AIDS patients with anti-retroviral treatment. Immunol Invest 2012;41(1):1-14
23. Landay A, da Silva BA, King MS, et al.: Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007;44(5):749-754
24. Vrisekoop N, van Gent R, de Boer AB, et al.: Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging. J Immunol 2008;181(2): 1573-1581
25. Dunham RM, Cervasi B, Brenchley JM, et al.: CD127 and CD25 expression defines CD4 + T cell subsets that are differentially depleted during HIV infection. J Immunol 2008;180(8):5582-5592
26. Benito JM, Lopez M, Lozano S, Gonzalez-Lahoz J, and Soriano V: Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4( + ) cells after antiretroviral therapy. J Infect Dis 2008;198(10):1466-1473
27. Kolber MA: CD38 + CD8 + T-cells negatively correlate with CD4 central memory cells in virally suppressed HIV-1-infected individuals. AIDS 2008;22(15):1937-1941
28. Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum CJ, and Chougnet CA: Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy. PloS One 2011;6(12):e28118
29. Lange CG, Lederman MM, Madero JS, et al.: Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002;30(1):33-40
30. Diaz A, Alos L, Leon A, et al.: Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. AIDS 2010;24(13):2029-2039
31. Diaz A, Garcia F, Mozos A, et al.: Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors. J Infect Dis 2011;203(6):810-813
32. Estes JD, Haase AT, and Schacker TW: The role of collagen deposition in depleting CD4 + T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Sem Immunol 2008;20(3):181-186
33. Estes J, Baker JV, Brenchley JM, et al.: Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008;198(4):456-464.